StocksRunner logo

Moderna RSV Vaccine Efficacy Disappoints, Stock Tumbles Amid Competitive Concerns

  • user  Shai.Gal
    Shai.Gal  Shai.Gal

    Shai Gal is a highly experienced financial journalist with expertise in the tech industry and dividend growth stocks. He has a strong track record of producing insightful content that helps investors make informed decisions. Shai is skilled in conducting in-depth research and analysis to identify trends and opportunities in the market.


stocks on the run


Key Highlights:

Moderna's RSV vaccine shows 50% efficacy after 18 months
Competitors GSK and Pfizer reported ~78% efficacy after two years
Company maintains 2024 sales forecast despite challenges
Moderna expects to break even by 2026, earlier than analysts predicted

Moderna's RSV Vaccine Faces Efficacy Hurdle


Moderna, a leading pharmaceutical company known for its mRNA technology, faced a setback as its shares plummeted 7% following the release of data on its respiratory syncytial virus (RSV) vaccine. The results have raised questions among investors about Moderna's ability to compete effectively with rivals Pfizer and GSK in the emerging RSV vaccine market for adults.


Last month, Moderna received approval from the U.S. Food and Drug Administration for its RSV vaccine, marking its entry into a potentially lucrative market. However, the recent efficacy data has cast a shadow over the company's prospects in this space.


Efficacy Concerns and Competitive Landscape


The crux of investor concern lies in the vaccine's efficacy data for the second year after administration. Moderna reported that its RSV vaccine was 50% effective in preventing RSV with three or more symptoms after 18 months. This figure pales in comparison to the results reported by competitors:

GSK's RSV vaccine showed 78.6% efficacy after two years
Pfizer's vaccine demonstrated 77.8% efficacy against RSV disease with three or more symptoms, also after two years

While direct comparisons between vaccines can be complex due to differences in trial designs and RSV season severity, the stark contrast in efficacy numbers has clearly unsettled investors. This isn't the first time Moderna has faced scrutiny over its RSV vaccine's durability. In February, the company's stock also took a hit when it presented eight-month efficacy data that was significantly lower than its four-month results.


Analyzing the Efficacy Data


Jefferies analysts have noted that the stock decline may be partly due to a misunderstanding of the data, particularly among non-biotech investors who are making simple comparisons between the efficacy numbers. The analysts emphasize that the comparison is more nuanced, given the differences in RSV season severity during the testing periods for each vaccine.


To put this in perspective, it's akin to comparing the effectiveness of a vaccine tested during a severe outbreak to one tested during a milder period. These contextual differences make direct comparisons challenging and potentially misleading.


Financial Performance and Future Outlook


Despite the RSV vaccine setback, Moderna's recent financial performance has shown some positive signs:

Q1 loss of $3.07 per share, better than analysts' expected loss of $3.58 per share
Revenues of $167 million, surpassing expectations of $125 million

Looking ahead, Moderna is maintaining its sales forecast for 2024, expecting to sell respiratory disease vaccines totaling $4 billion. However, this outlook hasn't sparked enthusiasm among investors, with the stock remaining flat in early trading.


The company anticipates that sales will be more concentrated in the second half of the year, with less than $300 million expected in the first half of 2024. Analysts project Moderna's revenues for the year to reach $4.19 billion, with $4.06 billion coming from product sales.


In a positive development, Moderna now expects to break even in 2026, earlier than previously anticipated. This projection contrasts with Wall Street expectations, which had the company losing $1.9 per share in 2026 and not achieving profitability until 2027.


For the full year, Moderna forecasts sales of $6 billion, which is lower than the consensus estimate of $6.9 billion. The cost of sales is expected to be $5 billion. Looking further ahead to 2024, the company projects revenues of $4 billion, significantly below Wall Street's expectations of $6.1 billion.


Investment Implications


For investors considering Moderna's stock, several factors should be weighed:

RSV Vaccine Market Potential: Despite the efficacy concerns, the RSV vaccine market remains a significant opportunity. Moderna's ability to improve its vaccine's performance or effectively market its current offering will be crucial.
Pipeline Diversity: Investors should consider Moderna's broader pipeline beyond the RSV vaccine, including its COVID-19 vaccines and other mRNA-based therapeutics.
Financial Health: The company's ability to beat earnings expectations and its earlier-than-anticipated break-even point are positive indicators of financial management.
Competitive Positioning: Moderna's performance relative to Pfizer and GSK in the RSV space will be a key factor to watch, as will its ability to maintain its position in the COVID-19 vaccine market.
Long-term Growth Potential: The company's mRNA technology platform continues to hold promise for addressing various diseases, which could drive future growth.



Moderna's recent RSV vaccine efficacy data has clearly rattled investors, leading to a significant stock decline. However, the company's overall financial performance and earlier break-even projections offer some counterbalance to these concerns. As the RSV vaccine market continues to evolve and Moderna works to address efficacy issues, investors will need to closely monitor the company's progress in this space as well as its broader pipeline developments.


While the current situation presents challenges, Moderna's innovative mRNA platform and its ability to bring products to market rapidly still make it a noteworthy player in the biotech sector. Investors should weigh the short-term setbacks against the long-term potential of the company's technology and pipeline when making investment decisions.


MRNA Stock Analysis

Last Price


Total Score

StocksRunner Raring Score
Strong Sell
Strong Buy




 Earnings are forecast to grow


 Trading below its fair value


 Investors confidence is positive


Risk Analysis


Risk Analysis

 Downgraded on weak valued


Risk Level

Risk Level

MRNA has Medium Risk Level. Click here to check what is your level of risk


Unlock insights and stay ahead in the stock market game. Click Here For More MRNA in-depth stock analysis.


stocks on the run


Unlock Exclusive Stock Insights!

Join for daily market updates, expert analyses, and actionable insights.

Signup now for FREE and stay ahead of the market curve!

Why Join?

Find out what 10,000+ subscribers already know.

Real-time insights for informed decisions.

Limited slots available, SignUp Now!

Login to Stocksrunner

Please note that the article should not be considered as investment advice or marketing, and it does not take into account the personal data and requirements of any individual. It is not a substitute for the reader's own judgment, and it should not be considered as advice or recommendation for buying or selling any securities or financial products.

StocksRunner logo

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future



StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

Receive our Daily Alerts

Discover the wisdom that over 10,000+ subscribers love! Join us for unique insights and keep ahead in the stock world. Just drop your email to get daily updates!

Our Services

Real-time stock market updates

Expert stock analysis

Investment strategies

Top stock recommendations

Trading signals and opportunities

About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy


Disclaimer: Past performance, whether explicitly stated or inferred from historical testing of methodologies, does not serve as an assurance of future outcomes or achievements. The displayed outcomes pertain to a strategy not historically accessible to investors and do not epitomize the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and aggregate score derive from a model retrospectively applied to historical data. This model is founded on assumptions intrinsic to its construct, which may remain unverifiable and expose stakeholders to potential losses. Engaging in active trading may not be advisable for individuals possessing limited financial resources, restricted investment or trading acumen, or a conservative risk profile. Please be advised that your invested capital is subject to inherent risks.

Kindly be informed that StocksRunner and its affiliated entities ("TS") neither extend nor endorse any proposition, invitation, or recommendation concerning the acquisition or divestiture of securities, derivatives, prospective products, or any form of investment guidance or strategy.

The information presented herein serves exclusively for illustrative purposes. It is imperative not to predicate investment decisions solely on the content of this platform. Prior to making any financial commitments, it is prudent to evaluate its relevance to your specific circumstances and consult with professionals specializing in financial, tax, and legal domains.

StocksRunner logo


Get the pulse of the market

StocksRunner logo

Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends


StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss


Receive our Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stocks analysis

Stocks trends

Stocks performance

Stocks analysis

Investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports


Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.